Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice #

Open access
Wang, Qiong, Jiang, Lei, Wang, Jue, Li, Shoufeng, Yu, Yue, You, Jia, Zeng, Rong, Gao, Xiang, Rui, Liangyou, Li, Wenjun, Liu, Yong·2009·Hepatology

Abstract

Hepatic steatosis is a hallmark of nonalcoholic fatty liver disease (NAFLD) and a key component of obesity-associated metabolic dysfunctions featuring dyslipidemia, insulin resistance, and loss of glycemic control. It has yet to be completely understood how much dysregulated de novo lipogenesis contributes to the pathogenic development of hepatic steatosis and insulin resistance. ATP-citrate lyase (ACL) is a lipogenic enzyme that catalyzes the critical reaction linking cellular glucose catabolism and lipogenesis, converting cytosolic citrate to acetyl-coenzyme A (CoA). Acetyl-CoA is further converted to malonyl-CoA, the essential precursor for fatty acid biosynthesis. We investigated whether dysregulation of hepatic ACL is metabolically connected to hepatic steatosis, insulin resistance, and hyperglycemia. We found that in leptin receptor–deficient db/db mice, the expression of ACL was selectively elevated in the liver but not in the white adipose tissue. Liver-specific ACL abrogation via adenovirus-mediated RNA interference prominently reduced the hepatic contents of both acetyl-CoA and malonyl-CoA, markedly inhibited hepatic de novo lipogenesis, and protected against hepatic steatosis in db/db mice. Surprisingly, liver-specific ACL abrogation markedly inhibited the expression of peroxisome proliferator-activated receptor-gamma and the entire lipogenic program in the liver. Moreover, hepatic ACL deficiency resulted in significantly down-regulated expression of gluconeogenic genes in the liver as well as enhanced insulin sensitivity in the muscle, leading to substantially improved systemic glucose metabolism. Conclusion: These findings establish a crucial role of hepatic ACL in lipid and glucose metabolism; therefore, hepatic ACL may serve as a potential target to treat NAFLD and type 2 diabetes. (Hepatology 2009.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.22774

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. NeuschwanderTetri, 2003, Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference., HEPATOLOGY, 37, 1202, 10.1053/jhep.2003.50193 · DOI · Paper page
  2. Adams, 2007, Nonalcoholic fatty liver disease., Ann Epidemiol, 17, 863, 10.1016/j.annepidem.2007.05.013 · DOI · Paper page
  3. Farrell, 2006, Nonalcoholic fatty liver disease: from steatosis to cirrhosis., HEPATOLOGY, 43, S99, 10.1002/hep.20973 · DOI · Paper page
  4. Brunt, 2007, Pathology of fatty liver disease., Mod Pathol, S40, 10.1038/modpathol.3800680 · DOI · Paper page
  5. Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome., HEPATOLOGY, 37, 917, 10.1053/jhep.2003.50161 · DOI · Paper page
  6. Wieckowska, 2007, Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future., HEPATOLOGY, 46, 582, 10.1002/hep.21768 · DOI · Paper page
  7. Watanabe, 2008, Liver diseases and metabolic syndrome., J Gastroenterol, 43, 509, 10.1007/s00535-008-2193-6 · DOI
  8. Rector, 2008, Nonalcoholic fatty liver disease and the metabolic syndrome: an update., World J Gastroenterol, 14, 185, 10.3748/wjg.14.185 · DOI · Paper page
  9. Postic, 2008, Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice., J Clin Invest, 118, 829, 10.1172/JCI34275 · DOI · Paper page
  10. Wakil, 1983, Fatty acid synthesis and its regulation., Ann Rev Biochem, 52, 537, 10.1146/annurev.bi.52.070183.002541 · DOI · Paper page
  11. Srere, 1959, The Citrate Cleavage Enzyme. I. Distribution and purification., J Biol Chem, 234, 2544, 10.1016/S0021-9258(18)69735-2 · DOI · Paper page
  12. Yu, 2003, Adipocytespecific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferatoractivated receptor gamma 1 (PPARgamma 1) overexpression., J Biol Chem, 278, 498, 10.1074/jbc.M210062200 · DOI · Paper page
  13. Herzig, 2003, CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR., Nature, 426, 190, 10.1038/nature02110 · DOI · Paper page
  14. Schultz, 2000, Role of LXRs in control of lipogenesis., Genes Dev, 14, 2831, 10.1101/gad.850400 · DOI · Paper page
  15. Shimano, 1999, Sterol regulatory elementbinding protein1 as a key transcription factor for nutritional induction of lipogenic enzyme genes., J Biol Chem, 274, 35832, 10.1074/jbc.274.50.35832 · DOI · Paper page
  16. Uyeda, 2006, Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis., Cell Metab, 4, 107, 10.1016/j.cmet.2006.06.008 · DOI · Paper page
  17. Denechaud, 2008, ChREBP, but not LXRs, is required for the induction of glucoseregulated genes in mouse liver., J Clin Invest, 118, 956
  18. Lewis, 2002, Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes., Endocr Rev, 23, 201, 10.1210/edrv.23.2.0461 · DOI · Paper page
  19. Mao, 2006, Liverspecific deletion of acetylCoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis., Proc Natl Acad Sci U S A, 103, 8552, 10.1073/pnas.0603115103 · DOI · Paper page
  20. Chakravarthy, 2005, New hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis., Cell Metab, 1, 309, 10.1016/j.cmet.2005.04.002 · DOI · Paper page
  21. Miyazaki, 2007, Hepatic stearoylCoA desaturase1 deficiency protects mice from carbohydrateinduced adiposity and hepatic steatosis., Cell Metab, 6, 484, 10.1016/j.cmet.2007.10.014 · DOI · Paper page
  22. Matsuzaka, 2007, Crucial role of a longchain fatty acid elongase, Elovl6, in obesityinduced insulin resistance., Nat Med, 13, 1193, 10.1038/nm1662 · DOI · Paper page
  23. Beigneux, 2004, ATPcitrate lyase deficiency in the mouse., J Biol Chem, 279, 9557, 10.1074/jbc.M310512200 · DOI
  24. Lin, 2005, Hyperlipidemic effects of dietary saturated fats mediated through PGC1 coactivation of SREBP., Cell, 120, 261, 10.1016/j.cell.2004.11.043 · DOI · Paper page
  25. Repa, 2000, Regulation of mouse sterol regulatory elementbinding protein1c gene (SREBP1c) by oxysterol receptors, LXRalpha and LXRbeta., Genes Dev, 14, 2819, 10.1101/gad.844900 · DOI · Paper page
  26. Lefebvre, 2006, Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis., J Clin Invest, 116, 571, 10.1172/JCI27989 · DOI · Paper page
  27. Mu, 1999, Quantitative trait loci analysis for the differences in susceptibility to atherosclerosis and diabetes between inbred mouse strains C57BL6J and C57BLKSJ., J Lipid Res, 40, 1328, 10.1016/S0022-2275(20)33495-7 · DOI
  28. Matsusue, 2003, Liverspecific disruption of PPARgamma in leptindeficient mice improves fatty liver but aggravates diabetic phenotypes., J Clin Invest, 111, 737, 10.1172/JCI200317223 · DOI · Paper page
  29. Pearce, 1998, The role of ATP citratelyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB204990, a lactone prodrug of the potent ATP citratelyase inhibitor SB201076., Biochem J, 334, 113, 10.1042/bj3340113 · DOI
  30. Dentin, 2006, Liverspecific inhibition of ChREBP improves hepatic steatosis and insulin resistance in obob mice., Diabetes, 55, 2159, 10.2337/db06-0200 · DOI · Paper page
  31. Leone, 1999, A critical role for the peroxisome proliferatoractivated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalphanull mouse as a model of fatty acid oxidation disorders., Proc Natl Acad Sci U S A, 96, 7473, 10.1073/pnas.96.13.7473 · DOI · Paper page
  32. Kersten, 1999, Peroxisome proliferatoractivated receptor alpha mediates the adaptive response to fasting., J Clin Invest, 103, 1489, 10.1172/JCI6223 · DOI · Paper page
  33. Memon, 2000, Upregulation of peroxisome proliferatoractivated receptors (PPARalpha) and PPARgamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPARgammaresponsive adipose tissuespecific genes in the liver of obese diabetic mice., Endocrinology, 141, 4021, 10.1210/endo.141.11.7771 · DOI · Paper page

Cited by

See all 213

Metadata

Authors
Wang, Q., Jiang, L., Wang, J., Li, S., Yu, Y., You, J., Zeng, R., Gao, X., Rui, L., Li, W., & Liu, Y.
Venue
Hepatology
Published
2009-04
Volume
49
Issue
4
Pages
1166-1175
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2028874440
Cited by
213
References
13
FWCI
3.07
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2344 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.